Studies conducted in patients with MS have shown that TSPO-PET binding in the NAWM, in the thalamus, and at the rim of chronic lesions, indicating microglia- and macrophage-related pathology, is predictive of later disease progression independent of relapse activity (PIRA) (78–80). This evidence concerns the gene TSPO and myeloid sarcoma.